Activity not yet confirmed Verified 5 Nov 2026
Adjuvant Capital
New York life sciences venture fund financing drugs, vaccines, diagnostics and devices for global public health needs such as infectious disease and maternal and child health.
- Type
- VC firm
- Location
- New York, New York, United States
- Backs
- Biotech and pharma
- Sectors
- Biotech, Healthtech and life sciences, Impact, Medtech
- Fund size / AUM
- $170.1M gross private fund assets (Form ADV; private funds: 2, of which venture capital: 2)
- Portfolio mix
- Biotech and pharma 85%; Medtech and digital health 10%; Consumer products 5% (n=19, 2020 to 2026)
- Website
- adjuvantcapital.com
Contacts on file
For Adjuvant Capital, the paid file holds: 8 named decision-makers with roles.
Get US Complete, $197 Free sample
One-time payment. No subscription. No account.
Notable investments
LimmaTech BiologicsMemo Therapeutics
Sources
- adviserinfo.sec.gov/firm/summary/301716
- adjuvantcapital.com/
- adjuvantcapital.com/portfolio/
- adjuvantcapital.com/team/
Last checked 5 Nov 2026. Is something wrong? Tell us.
Appears in 14 lists
Impact investors in New York (15)Biotech investors in New York (29)Medtech investors in New York (53)Impact venture capital firms in the US (55)Healthtech investors in New York (100)Impact investors (131)Biotech venture capital firms in the US (297)Medtech venture capital firms in the US (350)Venture capital firms in New York (440)Medtech investors (457)Biotech investors (484)Healthtech venture capital firms in the US (709)Healthtech investors (1,207)Venture capital firms in the US (2,975)